Melanoma Archives | MSD Oncology Clinical Trials

Um estudo do adjuvante pembrolizumabe/vibostolimabe versus pembrolizumabe para melanoma de alto risco ressecado em participantes com melanoma de estágio II-IV de alto risco

June 5, 2023

O objetivo principal deste estudo é comparar pembrolizumabe/vibostolimabe com pembrolizumabe com relação à sobrevida livre de recorrência (SLR). A hipótese primária é a de que pembrolizumabe/vibostolimabe é superior ao pembrolizumabe com relação à SLR, conforme avaliado pelo investigador, em participantes com melanoma de alto risco e ressecado em estágio IIB, IIC, III e IV.

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis

March 10, 2022

By Support_Clique

Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line Advanced Melanoma

March 10, 2022

By Support_Clique

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 Refractory Melanoma

March 10, 2022

By Support_Clique

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

March 10, 2022

By Support_Clique

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Estudo de pembrolizumabe em participantes pediátricos com tumor sólido avançado ou linfoma

March 10, 2022

By clique_admin

This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: advanced melanoma (6 months to

Segurança e eficácia de pembrolizumabe comparado ao placebo em melanoma ressecado de alto risco estágio II

March 7, 2022

By clique_admin

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either

Condition: Melanoma

Condition: Melanoma

Um estudo do adjuvante pembrolizumabe/vibostolimabe versus pembrolizumabe para melanoma de alto risco ressecado em participantes com melanoma de estágio II-IV de alto risco

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line Advanced Melanoma

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 Refractory Melanoma

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

Estudo de pembrolizumabe em participantes pediátricos com tumor sólido avançado ou linfoma

Segurança e eficácia de pembrolizumabe comparado ao placebo em melanoma ressecado de alto risco estágio II